PET Trial For Alzheimer’s Opens Door For CMS-Backed Research – Phurrough
This article was originally published in The Gray Sheet
Executive Summary
CMS' decision to fund the full costs of clinical trials assessing positron emission tomography to diagnose Alzheimer's disease marks a step toward the establishment of trial coverage as a viable national coverage decision alternative for the agency
You may also be interested in...
CMS-Supported Clinical Data Collection Worth The Cost – Tunis
CMS will seek public comments early this year on criteria for deciding which national coverage policies should include data collection requirements
CMS-Supported Clinical Data Collection Worth The Cost – Tunis
CMS will seek public comments early this year on criteria for deciding which national coverage policies should include data collection requirements
CMS To Help Build National FDG-PET Cancer Registry, Will Cover Trials
CMS plans to work with stakeholders to develop a national registry as well as small studies to determine the clinical utility of FDG-PET in the management of brain, ovarian, pancreatic and small-cell lung cancers